Century Therapeutics (IPSC) Operating Leases (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Operating Leases data on file, last reported at $43.9 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $43.9 million, down 8.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.9 million (down 8.06% YoY), and the FY2025 annual result was $40.2 million, down 17.81% from the prior year.
• Operating Leases rose to $43.9 million in Q1 2026 per IPSC's latest filing, from $40.2 million in the prior quarter.
• Over five years, Operating Leases peaked at $52.7 million in Q2 2024 and troughed at $14.4 million in Q1 2022.
• A 5-year average of $41.8 million and a median of $43.9 million in 2026 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases soared 185.29% in 2023, then decreased 18.99% in 2025.
• A 5-year view of Operating Leases shows it stood at $38.7 million in 2022, then gained by 20.57% to $46.7 million in 2023, then gained by 4.93% to $49.0 million in 2024, then decreased by 17.81% to $40.2 million in 2025, then climbed by 9.2% to $43.9 million in 2026.
• Business Quant data shows IPSC's Operating Leases at $43.9 million in Q1 2026, $40.2 million in Q4 2025, and $41.2 million in Q3 2025.